Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-005564
Filing Date
2025-04-25
Accepted
2025-04-25 16:30:21
Documents
65
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q avte-20250331x10q.htm   iXBRL 10-Q 1492751
2 EX-31.1 avte-20250331xex31d1.htm EX-31.1 9840
3 EX-31.2 avte-20250331xex31d2.htm EX-31.2 9861
4 EX-32.1 avte-20250331xex32d1.htm EX-32.1 5323
5 EX-32.2 avte-20250331xex32d2.htm EX-32.2 5359
  Complete submission text file 0001558370-25-005564.txt   6469829

Data Files

Seq Description Document Type Size
6 EX-101.SCH avte-20250331.xsd EX-101.SCH 36117
7 EX-101.CAL avte-20250331_cal.xml EX-101.CAL 49517
8 EX-101.DEF avte-20250331_def.xml EX-101.DEF 129650
9 EX-101.LAB avte-20250331_lab.xml EX-101.LAB 313305
10 EX-101.PRE avte-20250331_pre.xml EX-101.PRE 253055
68 EXTRACTED XBRL INSTANCE DOCUMENT avte-20250331x10q_htm.xml XML 1233486
Mailing Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451
Business Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40544 | Film No.: 25874589
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)